FDA Approves New ADC for HR+, HER2- Breast Cancer
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
AstraZeneca Gets FDA Approval for Metastatic Breast Cancer Treatment Datroway
AstraZeneca said the U.S. Food and Drug Administration approved Datroway, a treatment for metastatic breast cancer developed in combination with Daiichi Sankyo.
FDA Approves Datopotamab Deruxtecan for HR-Positive/HER2-Negative Metastatic Breast Cancer
The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday. The treatment, jointly developed with the Japanese company,
FDA approves new MCL treatment by AstraZeneca
WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation.
DATROWAY® Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
DATROWAY Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
Breast Cancer Rates Climb Among Younger Women
The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...
Targeted Oncology2h
Considering Sacituzumab in HR+, HER2- Breast Cancer After Progression
During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...
Hosted on MSN1d
Survival Benefit With Adjuvant T-DM1 in High-Risk HER2-Positive Breast Cancer
Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...
Science Daily13d
Approaches against metastatic breast cancer: mini-tumors from circulating cancer cells
Tumor cells circulating in the blood are the 'germ cells' of breast cancer metastases. They are very rare and could not be propagated in the culture dish until now, which made research into therapy ...
Allegheny Health Network introduces new program to help fight the grief of a breast cancer diagnosis
At Allegheny General Hospital, a new pilot program is focusing on patients diagnosed with metastatic breast cancer. It's a ...
AHN launches mental health support program for metastatic breast cancer patients
It’s been months in the making, but now the new resource is available for those battling the treatable, but incurable form of ...
Medscape8d
CDK 4/6 Blocker Prolongs Survival in HER2+ Metastatic Breast Cancer
Incredible” results from the PATINA trial suggested a new standard of care for HER2, ER-positive metastatic breast cancer.
The Macomb Daily on MSN4d
Macomb mom collaborates on children’s book for breast cancer families
The colorful picture book is helping parents of young children deal with the difficult journey that follows a breast cancer ...